What's hot

View all perspectives
What's Hot

What's new in sarcoidosis?

Watch video →

Rheumatoid Arthritis Comorbidities

Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.

Watch video →

Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders

  Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.

Watch video →

DMARDS, Prednisone, Pregnancy, OH MY!

Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos. 

Watch video →

Sarcopenia

Watch video →

Breathing New Insight into RA Interstitial Lung Disease

Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.

Watch video →

EULAR 2022 - Day 4 Faculty Panel Recap

Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.

Watch video →

Getting to the Heart of JAK Inhibitors

Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269. 

Watch video →

EULAR 2022 - Day 3 Faculty Panel Recap

Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.

Watch video →

Deucravacitinib at EULAR 2022

Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0

Watch video →
      RT @RichardPAConway: Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained i

      Richard Conway RichardPAConway

      3 years 6 months ago
      Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained improvements seen over time @RheumNow #EULAR2022 POS1028 https://t.co/VZhw6g4kCB
      RT @KDAO2011: “I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have ot

      TheDaoIndex KDAO2011

      3 years 6 months ago
      “I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow
      RT @RichardPAConway: Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consisten

      Richard Conway RichardPAConway

      3 years 6 months ago
      Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6
      RT @ericdeinmd: Kimme Hyrich:
      💉Risks of autoimmune flare is very low (3-5%)
      💉Flares are mild when present after C

      Eric Dein ericdeinmd

      3 years 6 months ago
      Kimme Hyrich: 💉Risks of autoimmune flare is very low (3-5%) 💉Flares are mild when present after COVID-19 vaccination Most unvaccinated patients did NOT identify as "anti-vax"... number 1 reason is concerns about their health #EULAR2022 @RheumNow @rheum_covid https://t.co/Ogn0raifPd
      RT @RichardPAConway: Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and c

      Richard Conway RichardPAConway

      3 years 6 months ago
      Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr
      RT @Janetbirdope: #SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should

      Janet Pope Janetbirdope

      3 years 6 months ago
      #SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj
      RT @Yuz6Yusof: #EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus &

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      #EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC
      RT @RichardPAConway: Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of ha

      Richard Conway RichardPAConway

      3 years 6 months ago
      Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52
      RT @AurelieRheumo: Does MTX have an impact on UST-immunogenicity in PsA?

      Post-hoc analysis from UST RCT in 110+ pts

      No

      Aurelie Najm AurelieRheumo

      3 years 6 months ago
      Does MTX have an impact on UST-immunogenicity in PsA? Post-hoc analysis from UST RCT in 110+ pts No difference in ADA rates & concentrations between MTX and non-MTX groups and ADA not associated w/ decreased UST levels POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT
      RT @KDAO2011: Don’t forget about the benefits of vaccines for diseases other than #COVID19 – Dr. K Hyrich #EULAR202

      TheDaoIndex KDAO2011

      3 years 6 months ago
      Don’t forget about the benefits of vaccines for diseases other than #COVID19 – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/86e93ugoBQ
      RT @ericdeinmd: Pneumonia and influenza risk higher in patients with rheumatic disease!
      Influenza Relative Risk: 1.2-3.3

      Eric Dein ericdeinmd

      3 years 6 months ago
      Pneumonia and influenza risk higher in patients with rheumatic disease! Influenza Relative Risk: 1.2-3.3 Pneumonia RR: shown to be up to 14.2 in SLE! 💉Vaccinations work! #EULAR2022 @Rheumnow @rheum_covid https://t.co/gvD1PaLQRe
      RT @RichardPAConway: Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of re

      Richard Conway RichardPAConway

      3 years 6 months ago
      Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of relatively similar efficacy in both groups. Surprising that the difference is not greater given refractory GCA inherently more complex @RheumNow #EULAR2022 POS0817 https://t.co/HEWzYCz9YD
      RT @KDAO2011: Proof that vaccines work in our rheum patients; reduction in hospitalization, ICUs, death – Dr. K Hyrich

      TheDaoIndex KDAO2011

      3 years 6 months ago
      Proof that vaccines work in our rheum patients; reduction in hospitalization, ICUs, death – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/u8PWvgfdiC
      RT @ericdeinmd: #EULAR2022:
      Kimme Hyrich: Think about Herpes zoster risk in ALL rheumatic disease patients (not just, bu

      Eric Dein ericdeinmd

      3 years 6 months ago
      #EULAR2022: Kimme Hyrich: Think about Herpes zoster risk in ALL rheumatic disease patients (not just, but particularly with JAKs). 💉Avoid Zostavax (Live) in patients on immunosuppression 💉Warn side effects are common with Shingrix @RheumNow @rheum_covid https://t.co/w7p4oHuqL9
      RT @RichardPAConway: 2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements acro

      Richard Conway RichardPAConway

      3 years 6 months ago
      2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt

      Podcasts

      • CD19 CAR T Cell Therapy In SLE (9.16.2022) 00:19:20
      • Does Fibromyalgia Need B12 00:27:04
      • StillsNow Podcast August 2022 - Genetic Testing for Autoinflammatory Diseases 00:28:27

      Catch up on Conference Podcasts

      ×